{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:59:30Z","timestamp":1788962370648,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.14310\/horm.2002.1319","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T20:39:09Z","timestamp":1391114349000},"page":"280-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["The use of bisphosphonates in women prior to or during pregnancy and lactation"],"prefix":"10.1007","volume":"10","author":[{"given":"Stathopoulos P.","family":"Ioannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liakou G.","family":"Chrysoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsalira","family":"Aikaterini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trovas","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyritis P.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papaioannou A.","family":"Nikolaos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tournis","family":"Symeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"10040280_CR1","unstructured":"Top 200 brand-name drugs by units in 2006.\u201d https:\/\/doi.org\/www.drug-topics.com\/drugtopics\/Pharmacy+Facts+And+Figures\/Top-200-brand-name-drugs-by-units-in-2006."},{"key":"10040280_CR2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S, 2008 Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032\u20131045.","journal-title":"Mayo Clin Proc"},{"key":"10040280_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","volume":"60","author":"N Patlas","year":"1999","unstructured":"Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A, 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60: 68\u201373.","journal-title":"Teratology"},{"key":"10040280_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1006\/taap.1993.1148","volume":"121","author":"DH Minsker","year":"1993","unstructured":"Minsker DH, Manson JM, Peter CP, 1993 Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121: 217\u2013223.","journal-title":"Toxicol Appl Pharmacol"},{"key":"10040280_CR5","first-page":"654","volume":"42","author":"P Graepel","year":"1992","unstructured":"Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR, 1992 Reproduction toxicity studies with pamidronate. Arzneimittelforschung 42: 654\u2013667.","journal-title":"Arzneimittelforschung"},{"key":"10040280_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.reprotox.2006.05.009","volume":"22","author":"A Ornoy","year":"2006","unstructured":"Ornoy A, Wajnberg R, Diav-Citrin O, 2006 The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22: 578\u2013579.","journal-title":"Reprod Toxicol"},{"key":"10040280_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bone.2008.11.001","volume":"44","author":"S Levy","year":"2009","unstructured":"Levy S, Fayez I, Taguchi N, et al, 2009 Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44: 428\u2013430.","journal-title":"Bone"},{"key":"10040280_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.autrev.2010.03.002","volume":"9","author":"I Losada","year":"2010","unstructured":"Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A, 2010 Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev 9: 547\u2013552.","journal-title":"Autoimmun Rev"},{"key":"10040280_CR9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1210\/jc.2005-2548","volume":"91","author":"B Chan","year":"2006","unstructured":"Chan B, Zacharin M, 2006 Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91: 2017\u20132020.","journal-title":"J Clin Endocrinol Metab"},{"key":"10040280_CR10","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1359\/JBMR.040711","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Ward L, Glorieux FH, 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742\u20131745.","journal-title":"J Bone Miner Res"},{"key":"10040280_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00198-009-0983-1","volume":"21","author":"S Hassen-Zrour","year":"2010","unstructured":"Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N, 2010 Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int 21: 709\u2013710.","journal-title":"Osteoporos Int"},{"key":"10040280_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00063-001-1066-z","volume":"96","author":"IA Harsch","year":"2001","unstructured":"Harsch IA, Hubner RH, Hahn EG, Hensen J, 2001 [Osteoporosis and multiple pregnancy--a case report with positive outcome]. Med Klin (Munich) 96: 402\u2013407.","journal-title":"Med Klin (Munich)"},{"key":"10040280_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00404-007-0321-9","volume":"276","author":"S Athimulam","year":"2007","unstructured":"Athimulam S, Chan P, Baker M, Nauta M, Yoong W, 2007 The effect of pregnancy on pre-existing osteopenia: a case report. Arch Gynecol Obstet 276: 175\u2013177.","journal-title":"Arch Gynecol Obstet"},{"key":"10040280_CR14","doi-asserted-by":"crossref","unstructured":"Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M, 2011 Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int, in press.","DOI":"10.1007\/s00296-011-1816-z"},{"key":"10040280_CR15","first-page":"344","volume":"25","author":"FR Cabar","year":"2007","unstructured":"Cabar FR, Nomura RM, Zugaib M, 2007 Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol 25: 344\u2013345.","journal-title":"Clin Exp Rheumatol"},{"key":"10040280_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/bdra.10016","volume":"67","author":"AR Rutgers-Verhage","year":"2003","unstructured":"Rutgers-Verhage AR, deVries TW, Torringa MJ, 2003 No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol 67: 203\u2013204.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10040280_CR17","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00198-009-1138-0","volume":"21","author":"SR Mastaglia","year":"2010","unstructured":"Mastaglia SR, Watman NP, Oliveri B, 2010 Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. Osteoporos Int 21: 1959\u20131962.","journal-title":"Osteoporos Int"},{"key":"10040280_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","volume":"14","author":"PN Biswas","year":"2003","unstructured":"Biswas PN, Wilton LV, Shakir SA, 2003 Pharmacovigilance study of alendronate in England. Osteoporos Int 14: 507\u2013514.","journal-title":"Osteoporos Int"},{"key":"10040280_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.49.11.955-a","volume":"49","author":"DJ Dunlop","year":"1990","unstructured":"Dunlop DJ, Soukop M, McEwan HP, 1990 Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49: 955.","journal-title":"Ann Rheum Dis"},{"key":"10040280_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0936-6555(05)80667-3","volume":"8","author":"TM Illidge","year":"1996","unstructured":"Illidge TM, Hussey M, Godden CW, 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257\u2013258.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10040280_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ygyno.2004.06.037","volume":"95","author":"C Andreadis","year":"2004","unstructured":"Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D, 2004 Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol 95: 252\u2013255.","journal-title":"Gynecol Oncol"},{"key":"10040280_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/01.AOG.0000209183.39581.e9","volume":"108","author":"EC Culbert","year":"2006","unstructured":"Culbert EC, Schfirin BS, 2006 Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol 108: 789\u2013791.","journal-title":"Obstet Gynecol"},{"key":"10040280_CR23","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1359\/jbmr.2000.15.10.2052","volume":"15","author":"K Siminoski","year":"2000","unstructured":"Siminoski K, Fitzgerald AA, Flesch G, Gross MS, 2000 Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15: 2052\u20132055.","journal-title":"J Bone Miner Res"},{"key":"10040280_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1148\/radiology.168.1.3380967","volume":"168","author":"WR Hedrick","year":"1998","unstructured":"Hedrick WR, DiSimone RN, Wolf BH, Langer A, 1998 Absorbed dose to the fetus during bone scintigraphy. Radiology 168: 245\u2013248.","journal-title":"Radiology"},{"key":"10040280_CR25","first-page":"370","volume":"27","author":"CJ Palestro","year":"1986","unstructured":"Palestro CJ, Malat J, Collica CJ, Richman AH, 1986 Incidental diagnosis of pregnancy on bone and gallium scintigraphy. J Nucl Med 27: 370\u2013372.","journal-title":"J Nucl Med"},{"key":"10040280_CR26","first-page":"1338","volume":"35","author":"AF McKenzie","year":"1994","unstructured":"McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ, 1994 Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 35: 1338\u20131341.","journal-title":"J Nucl Med"},{"key":"10040280_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1359\/jbmr.2000.15.3.557","volume":"15","author":"AJ Black","year":"2000","unstructured":"Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD, 2000 A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 15: 557\u2013563.","journal-title":"J Bone Miner Res"},{"key":"10040280_CR28","unstructured":"Kovacs C, 2006 Skeletal physiology: fetus and neonate. Primer on the metabolic bone diseases and disorders of mineral metabolism, pp; 50\u201355."},{"key":"10040280_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, et al, 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617\u2013627.","journal-title":"Bone"},{"key":"10040280_CR30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, et al, 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235\u2013242.","journal-title":"J Pharmacol Exp Ther"},{"key":"10040280_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH, 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75\u201385.","journal-title":"Bone"},{"key":"10040280_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"SC Cremers","year":"2005","unstructured":"Cremers SC, Pillai G, Papapoulos SE, 2005 Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551\u2013570.","journal-title":"Clin Pharmacokinet"},{"key":"10040280_CR33","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/154405910708601102","volume":"86","author":"DB Kimmel","year":"2007","unstructured":"Kimmel DB, 2007 Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86: 1022\u20131033.","journal-title":"J Dent Res"},{"key":"10040280_CR34","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","volume":"12","author":"SA Khan","year":"1997","unstructured":"Khan SA, Kanis JA, Vasikaran S, et al, 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12: 1700\u20131707.","journal-title":"J Bone Miner Res"},{"key":"10040280_CR35","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMc062792","volume":"356","author":"SE Papapoulos","year":"2007","unstructured":"Papapoulos SE, Cremers SC, 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356: 1075\u20131076.","journal-title":"N Engl J Med"},{"key":"10040280_CR36","first-page":"706","volume":"49","author":"P Peris","year":"2011","unstructured":"Peris P, Torra M, Olivares V, et al, 2011 Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49: 706\u2013709.","journal-title":"Relationship with bone turnover. Bone"},{"key":"10040280_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","volume":"33","author":"YZ Bagger","year":"2003","unstructured":"Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C, 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33: 301\u2013307.","journal-title":"Bone"},{"key":"10040280_CR38","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1210\/jcem.80.12.8530584","volume":"80","author":"JO Landman","year":"1995","unstructured":"Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE, 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 3465\u20133468.","journal-title":"J Clin Endocrinol Metab"},{"key":"10040280_CR39","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, et al, 2004 Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189\u20131199.","journal-title":"N Engl J Med"},{"key":"10040280_CR40","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, et al, 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927\u20132938.","journal-title":"JAMA"},{"key":"10040280_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP, et al, 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365\u2013672.","journal-title":"Osteoporos Int"},{"key":"10040280_CR42","first-page":"1205","volume-title":"Medical Physiology","author":"A Guyton","year":"1992","unstructured":"Guyton A 1992. Medical Physiology, Paschalidis eds, Athens; pp, 1205\u20131207."},{"key":"10040280_CR43","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, et al, 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253\u20131263.","journal-title":"Lancet"},{"key":"10040280_CR44","unstructured":"Ott SM, 2004 Effects of bisphosphonates during pregnancy. https:\/\/doi.org\/courses.washington.edu\/bonephys\/oppregnancy.html#Bis. 2010 November, 26."}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1319\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:35:46Z","timestamp":1739115346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10040280"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1319","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"28 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}